PB2107 Mim8 (denecimig) prophylaxis in adults, adolescents and children with haemophilia A with or without inhibitors: Interim patient-reported outcomes from the long-term extension study (FRONTIER4)

Denecimig (Mim8) is a next-generation, activated factor VIII mimetic intended for subcutaneous prophylaxis of haemophilia A with or without factor VIII inhibitors (HAwI/HA). In FRONTIER2 (NCT05053139), denecimig reduced joint pain (Joint Pain Rating Scale [JPRS]) and treatment burden (Haemophilia Treatment Experience Measure [Hemo-TEM]) in adults and adolescents, with >90% preferring it to previous treatment, according to the Haemophilia Patient Preference Questionnaire. In the FRONTIER3 (NCT05306418) study among children aged 1-11 years, denecimig reduced treatment burden according to child-Hemo-TEM.